Zacks Small-Cap Research

Sponsored – Impartial – Comprehensive

February 3, 2023
John D. Vandermosten, CFA
312-265-9588 / jvandermosten@zacks.com

scr.zacks.com **10 S. Riverside Plaza, Suite 1600, Chicago, IL 60606**

Vyant Bio, Inc. (VYNT: NASDAQ)

Withdrawing Valuation

We withdraw our valuation.

Current Price (2/2/2023)	$1.03
Valuation	**NA**

OUTLOOK

Vyant Bio's drug discovery platform uses human-derived organoid models of brain disease guided by artificial intelligence and machine learning. It screens thousands of candidates seeking prospective compounds that rescue the diseased organoid phenotype to a healthy, non-disease state, which Vyant believes is a biomarker for clinical efficacy.

Vyant features several programs in late preclinical development in Rett Syndrome (RTT) and CDKL5 Deficiency Disorder (CDD). The most advanced candidate is donepezil, a generic drug for Alzheimer's disease. It has rescued the RTT phenotype & with further work, expected to validate the platform. The RTT program is a new chemical entity identified in collaboration with partner Atomwise. The CDD program is a joint effort with Cyclica to identify a candidate using *in silico* screening and organoids.

Both RTT and CDD are rare diseases and attractive indications for proving the company's discovery platform. Rett affects every 1:10-15,000 while CDD appears in every 1:40-60,000. Both disorders are substantially more common in girls.

If Vyant is successful in validating the platform with successful advances in Rett and CDD, it will pursue additional indications such as Parkinson's disease and partner with others seeking to advance their own platforms.

SUMMARY DATA

52-Week High	**$9.85**
52-Week Low	**$0.66**
One-Year Return (%)	**-91.0**
Beta	**1.8**
Average Daily Volume (sh)	**408,987**
Shares Outstanding (mil)	**5.91**
Market Capitalization ($mil)	**4.9**
Short Interest Ratio (days)	**0.8**
Institutional Ownership (%)	**6.4**
Insider Ownership (%)	**24.8**
Annual Cash Dividend	**$0.00**
Dividend Yield (%)	**0.00**
5-Yr. Historical Growth Rates	
Sales (%)	**N/A**
Earnings Per Share (%)	**N/A**
Dividend (%)	**N/A**
P/E using TTM EPS	**N/A**
P/E using 2022 Estimate	**N/A**
P/E using 2023 Estimate	**N/A**
Zacks Rank	**N/A**

Risk Level	**Above Average**
Type of Stock	**Small-Growth**
Industry	**Biomedical/Genetics**

ZACKS ESTIMATES

Revenue
(In millions of USD)

	Q1 (Mar)	Q2 (Jun)	Q3 (Sep)	Q4 (Dec)	Year (Dec)
2021					$1.1 A
2022	$0.3 A	$0.2 A	$0.2 A	$0.0 E	$0.7 E
2023					$0.0 E
2024					$0.0 E

Earnings per Share

	Q1 (Mar)	Q2 (Jun)	Q3 (Sep)	Q4 (Dec)	Year (Dec)
2021					-$4.11 A
2022	-$0.76 A	-$0.74 A	-$0.62 A	-$0.61 E	-$2.72 E
2023					-$2.38 E
2024					-$2.19 E

© Copyright 2023, Zacks Investment Research. All Rights Reserved.

WHAT'S NEW

Cash Preservation and Reduction in Force

Vyant Bio, Inc. (NASDAQ: VYNT) surprised us with what may be a wind down of the company. The CFO and CSO of the company stepped down to conserve cash and the CFO takes on all the executive responsibilities as the company works through strategic alternatives. A core group of employees have been retained to efficiently effect a transaction or orderly wind down of the company. Vyant also expects to delay or defer its pre-clinical and clinical programs. Vyant recently engaged with LifeSci Capital to look into various alternatives for the company, which may include a sale. In order to preserve corporate assets, Vyant has reduced its workforce. We withdraw our target price based on uncertainty regarding the company's future.

PROJECTED FINANCIALS

Vyant Bio, Inc. - Income Statement


Vyant Bio, Inc.	2021 A	Q1 A	Q2 A	Q3 A	Q4 E	2022 E	2023 E	2024 E
Total Revenues ($US '000)	**$1,148**	**$303**	**$165**	**$152**	**$48**	**$668**	**$0**	**$0**
YOY Growth	*32%*	*49%*	*-50%*	*-90%*	*-87%*	*-42%*	*-100%*	*# DIV/0!*
Cost of Goods Sold, Service	$408	$38	$0	$0	$0	$38	$0	$0
Gross Margin	39%	60%	0%	0%	0%	60%	0%	0%
Cost of Goods Sold, Product	$1,439	$348	$304	$257	$89	$998	$0	$0
Gross Margin	-198%	-67%	-84%	-69%	-85%	-74%	0%	0%
Research & Development	$4,273	$1,551	$1,688	$1,993	$1,700	$6,932	$9,000	$10,200
Selling, General & Administrative	$8,424	$2,763	$2,509	$1,583	$1,825	$8,680	$6,200	$6,250
Other Costs	$2,310	$0	$0	$0	$0	$0	$0	$0
Income from operations	($15,706)	($4,397)	($4,336)	($3,681)	($3,566)	($15,980)	($15,200)	($16,450)
Operating Margin	*-1368%*	*-1451%*	*-2628%*	*-2422%*	*-7429%*	*-2392%*	*# DIV/0!*	*# DIV/0!*
Other Income	($2,869)	($9)	$11	$34				
Pre-Tax Income	($18,575)	($4,406)	($4,325)	($3,647)	($3,566)	($15,980)	($15,200)	($16,450)
Tax Rate	*0.0%*	*0.0%*	*0.0%*	*0.0%*	*0.0%*	*0.0%*	*0.0%*	*0.0%*
Net Income	**($18,575)**	**($4,406)**	**($4,325)**	**($3,647)**	**($3,566)**	**($15,944)**	**($15,200)**	**($16,450)**
Net Margin								
Reported EPS	**($4.11)**	**($0.76)**	**($0.74)**	**($0.62)**	**($0.61)**	**($2.72)**	**($2.38)**	**($2.19)**
YOY Growth								
Basic Shares Outstanding	4,523	5,803	5,883	5,883	5,883	5,863	6,400	7,500

Source: Company Filing // Zacks Investment Research, Inc. Estimates

© Copyright 2023, Zacks Investment Research. All Rights Reserved.

HISTORICAL STOCK PRICE

Vyant Bio, Inc. – Share Price Chart[1]



[1] Source: Zacks Research System

DISCLOSURES

The following disclosures relate to relationships between Zacks Small-Cap Research ("Zacks SCR"), a division of Zacks Investment Research ("ZIR"), and the issuers covered by the Zacks SCR Analysts in the Small-Cap Universe.

ANALYST DISCLOSURES

I, John Vandermosten, hereby certify that the views expressed in this research report accurately reflect my personal views about the subject securities and issuers. I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the recommendations or views expressed in this research report. I believe the information used for the creation of this report has been obtained from sources I considered to be reliable, but I can neither guarantee nor represent the completeness or accuracy of the information herewith. Such information and the opinions expressed are subject to change without notice.

INVESTMENT BANKING AND FEES FOR SERVICES

Zacks SCR does not provide investment banking services nor has it received compensation for investment banking services from the issuers of the securities covered in this report or article.

Zacks SCR has received compensation from the issuer directly, from an investment manager or from an investor relations consulting firm engaged by the issuer for providing non-investment banking services to this issuer and expects to receive additional compensation for such non-investment banking services provided to this issuer. The non-investment banking services provided to the issuer includes the preparation of this report, investor relations services, investment software, financial database analysis, organization of non-deal road shows, and attendance fees for conferences sponsored or co-sponsored by Zacks SCR. The fees for these services vary on a per-client basis and are subject to the number and types of services contracted. Fees typically range between ten thousand and fifty thousand dollars per annum. This research report was prepared under the aforementioned engagement.

POLICY DISCLOSURES

This report provides an objective valuation of the issuer today and expected valuations of the issuer at various future dates based on applying standard investment valuation methodologies to the revenue and EPS forecasts made by the SCR Analyst of the issuer's business.
SCR Analysts are restricted from holding or trading securities in the issuers that they cover. ZIR and Zacks SCR do not make a market in any security followed by SCR nor do they act as dealers in these securities. Each Zacks SCR Analyst has full discretion over the valuation of the issuer included in this report based on his or her own due diligence. SCR Analysts are paid based on the number of companies they cover.
SCR Analyst compensation is not, was not, nor will be, directly or indirectly, related to the specific valuations or views expressed in any report or article.

ADDITIONAL INFORMATION

Additional information is available upon request. Zacks SCR reports and articles are based on data obtained from sources that it believes to be reliable, but are not guaranteed to be accurate nor do they purport to be complete. Because of individual financial or investment objectives and/or financial circumstances, this report or article should not be construed as advice designed to meet the particular investment needs of any investor. Investing involves risk. Any opinions expressed by Zacks SCR Analysts are subject to change without notice. Reports or articles or tweets are not to be construed as an offer or solicitation of an offer to buy or sell the securities herein mentioned.

© Copyright 2023, Zacks Investment Research. All Rights Reserved.